Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
13 evidence topics · 11 sources
Summary
A 2026 guideline (Vázquez et al.) recommends that all patients with HAE be evaluated for long-term prophylaxis at every visit through shared decision-making, and lists subcutaneous plasma-derived C1 inhibitor, lanadelumab, berotralstat, garadacimab, and donidalorsen as first-line options. The 2026 pediatric guideline recommends lanadelumab or plasma-derived C1 inhibitor for children aged between 6 and 12 years, and adds berotralstat and garadacimab for adolescents aged 12 years or older. Both guidelines recommend supplying on-demand treatment for at least 2 attacks during prophylaxis, and the Vázquez et al. guideline recommends management by physicians with expertise in HAE supported by a referral center.
Onvuzosiran is an investigational small interfering RNA and appears in no guideline list of first-line agents. The sponsor is developing it for prevention of HAE attacks as a subcutaneous injection every 3 or 6 months, both intervals being studied in the phase 3 STOP-HAE trial, and a 2025 review describes it as in development for long-term prophylaxis in HAE type I/II. STOP-HAE requires participants to complete any washout of long-term prophylaxis before screening and to have access to an acute therapy, so its results will describe onvuzosiran as the only long-term prophylactic agent, compared with placebo, with on-demand treatment available. The sources do not state whether onvuzosiran would be self-administered or given by a health care professional; the guideline states that self-administration and home therapy are available for current agents including lanadelumab, garadacimab, and donidalorsen.
Other prophylactic agents in late-stage development include navenibart, a plasma kallikrein inhibitor dosed subcutaneously every 3 or 6 months in a phase 3 trial with top-line results expected in Q3 2027; deucrictibant XR, with an NDA submission planned for the first half of 2027; lonvoguran ziclumeran, intended as a single-dose therapy, with a PDUFA target action date of March 10, 2027; and BW-20805, a second prekallikrein-directed siRNA dosed every 12 or 24 weeks in a study of 25 participants with HAE.
Evaluation for long-term prophylaxis: guideline recommendation
“We recommend that all patients with HAE are evaluated for LTP at every visit, with a shared decision-making approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Successful LTP implies full disease control with minimal treatment burden and requires patient adherence, so that a shared decision-making approach is essential.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line long-term prophylaxis agents: WAO guideline
Pediatric guideline: criteria and first-line agents by age
“We recommend evaluating frequency and location of angioedema attacks, burden of disease, quality of life, patients' and caregivers' preferences, and availability of medications when considering long‐term prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In children with hereditary angioedema due to C1 inhibitor deficiency aged between 6 and 12 years, we recommend the use of lanadelumab or plasma‐derived C1 inhibitor as first‐line long‐term prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adolescents with hereditary angioedema due to C1 inhibitor deficiency aged 12 years or older, we recommend the use of any of the following treatments: berotralstat or garadacimab or lanadelumab or plasma‐derived C1 inhibitor, as first‐line long‐term prophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Criteria for starting long-term prophylaxis: health technology assessment
Onvuzosiran in guideline and review discussion of investigational agents
Sponsor-stated intended use and dosing intervals
Sponsor-stated rationale relative to current prophylaxis
Phase 3 trial population: discontinuation of prior prophylaxis
Pipeline: navenibart, long-acting plasma kallikrein inhibitor
“Navenibart, a human monoclonal antibody targeting plasma kallikrein and engineered with Fc region modifications that extend its half-life to approximately 100 days, has advanced into phase 3 clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote